Bristol Myers Squibb Completes Acquisition of Karuna …
WEBMar 18, 2024 — Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio. KarXT, Karuna’s Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications. PRINCETON, N.J.-- (BUSINESS WIRE)-- …
BMS wins approval for schizophrenia drug acquired from Karuna
WEB13 hours ago — Originally developed by Karuna Therapeutics and named KarXT, BMS inherited the drug as part of a $14bn acquisition, which was finalised in March 2024. The acquisition is set to pay off as Cobenfy is set to pull in $2.99bn in sales in 2030, according to GlobalData forecasts. GlobalData is the parent company of Pharmaceutical Technology.
Karuna Therapeutics Announces Positive Results from Phase 3 …
WEBAug 8, 2022 — BOSTON-- ( BUSINESS WIRE )--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with...
Bristol Myers Squibb Strengthens Neuroscience Portfolio with ...
WEBDec 22, 2023 — Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics. Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety. KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in …
Karuna Therapeutics Announces Positive Results from Phase 1b …
WEBBOSTON, November 16, 2023 -- (BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people...
Bristol Myers to Acquire the Drugmaker Karuna for $14 Billion
WEBDec 22, 2023 — Bristol Myers Squibb, the global pharmaceutical giant, said on Friday that it would acquire Karuna Therapeutics, which makes drugs to treat schizophrenia and Alzheimer’s, in an all-cash deal...
Karuna Therapeutics Announces The Lancet Publication of Data …
WEBBOSTON, December 14, 2023--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with...
Bristol Myers Squibb to buy Karuna Therapeutics - CNBC
WEBDec 22, 2023 — Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna's stock closed up more than 47% on the ...
PureTech-Invented KarXT Receives U.S. Food and Drug …
WEB1 day ago — The FDA approval triggers two separate milestone payments to PureTech totaling $29 million under agreements with Royalty Pharma and PureTech’s Founded Entity, Karuna Therapeutics, which was ...
WEBBristol Myers Squibb to Acquire Karuna Therapeutics. December 22, 2023. Forward Looking Statements. Additional Information and Where to Find it. In connection with the proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb, Karuna Therapeutics intends to file a preliminary and definitive proxy statement.
Skip to content